Sitari Pharmaceuticals raises $10 mln
Sitari Pharmaceuticals has raised $10 million in Series A financing and R&D support from Avalon Ventures and GlaxoSmithKline. Sitari is developing treatments for celiac disease. Sitari's funding is a product of a $496 million alliance forged between Avalon and GSK in April to back startups in San Diego. GSK reportedly committed the bulk of the $495 million.
22 November 2013•4 mins read
